J. Cheng

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · Annals of Oncology · 2018 · 134 citations

Medicine, R/m Hnscc, Pathology +8

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

Irene Braña, Raanan Berger, Talia Golan et al. · British Journal of Cancer · 2014 · 88 citations · Full text

A Phase 1B Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Advanced Gastric Cancer

Kei Muro, Yung‐Jue Bang, Veena Shankaran et al. · Annals of Oncology · 2014 · 63 citations · Full text

Phase 1B, Gastrointestinal Oncology, Advanced Gastric Cancer +7

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

Margaret von Mehren, Russell J. Schilder, J. Cheng et al. · Annals of Oncology · 2008 · 51 citations · Full text

Pegylated Liposomal Doxorubicin, Health Sciences, Medicine +10

A Phase 1B Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Advanced Urothelial Tract Cancer

Elizabeth R. Plimack, Shilpa Gupta, Joaquim Bellmunt et al. · Annals of Oncology · 2014 · 51 citations · Full text

Phase 1B, Urology, Genitourinary Cancer +4